Abstracts tagged "Rheumatoid Factor"

Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Heinrich-Karl Greenblatt¹, Ted Mikuls², Jess Edison³, Marie Feser⁴, Mark Parish⁵, LauraKay Moss⁵, Elizabeth Mewshaw⁶ and Kevin D. Deane⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Nebraska Medical Center, Omaha, NE, ³Walter Reed National Military Medical Center, Bethesda, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…
Abstract Number: 1753 • ACR Convergence 2020
Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention
Sara Eileen Meyer¹, Julianna Rachel Hoeper², Kirsten Hoeper¹, Torsten Witte³ and Dirk Meyer-Olson⁴, ¹Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, ²Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, ³Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, ⁴Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 464 • 2019 ACR/ARP Annual Meeting
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Takayoshi Owada¹, Kazuhiro Kurasawa ¹, Yuta Takamura ¹, Toshiyuki Miyao ¹, Ayae Tanaka ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Reika Maezawa ¹ and Masafumi Arima ¹, ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan
Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…
Abstract Number: 51 • 2019 ACR/ARP Annual Meeting
Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Yuki Ishikawa¹, Motomu Hashimoto ², Katsunori Ikari ³, Koichiro Ohmura ⁴, Masao Tanaka ⁴, Hiromu Ito ⁴, Atsuo Taniguchi ³, Hisashi Yamanaka ³, Tsuneyo Mimori ⁴ and Chikashi Terao ⁵, ¹Joslin Diabes Center, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵RIKEN, Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), cigarette smoking affects both rheumatoid factor (RF) and anti-citrullinated cyclic peptide/protein antibody (ACPA) production, but its association in relation to…
Abstract Number: 211 • 2018 ACR/ARHP Annual Meeting
Excess in Prevalence of Functional Disability in Patients with Rheumatoid Arthritis: Does Serologic Status Matter?
Elena Myasoedova¹, John M. Davis III¹, Sara J. Achenbach², Eric L. Matteson¹ and Cynthia S. Crowson², ¹Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA) over the recent decades, many patients with RA do not achieve remission or full physical…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 568 • 2018 ACR/ARHP Annual Meeting
Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial
Renaud Felten¹, Marie-Alexandra Alyanakian², Lucienne Chatenoud², Jean Sibilia¹, Frédérique Gandjbakhch³, Cédric Lukas⁴ and Jacques-Eric Gottenberg¹, ¹University Hospital of Strasbourg, Department of Rheumatology, Strasbourg, France, ²Laboratoire d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Paris, France, ³Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France, ⁴University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), little is known about the prognostic relevance of the change in autoantibody (ab) levels. Seroconversion was reported to be associated…
Abstract Number: 1452 • 2018 ACR/ARHP Annual Meeting
Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis
Shinya Kawashiri¹, Keita Fujikawa², Ayako Nishino¹, Ayuko Takatani¹, Toshimasa Shimizu¹, Masataka Umeda¹, Shoichi Fukui¹, Takashi Igawa¹, Tomohiro Koga¹, Naoki Iwamoto¹, Kunihiro Ichinose¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Background/Purpose: We conducted this retrospective study to determine objective and comprehensive diagnostic criteria for early rheumatoid arthritis (RA) that are based on ultrasound (US) and…
Abstract Number: 1470 • 2018 ACR/ARHP Annual Meeting
Russell Bodies and Serological Status in Rheumatoid Arthritis
Michael A. McNamara¹, Susan M. Goodman², Laura T. Donlin³, Dana Orange⁴, Serene Z. Mirza¹, Jackie Szymonifka², Mark P. Figgie⁵, Vivian P. Bykerk² and Edward F. DiCarlo⁶, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁴Rockefeller University, New York, NY, ⁵Surgery, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY
Russell Bodies and Serological Status in Rheumatoid Arthritis Background/Purpose: Russell bodies (RBs) are globular aggregates of immunoglobulin produced by plasma cells and identified both within…
Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Peter M. Maloley¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Michael J. Duryee³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima² and Naoki Ishiguro², ¹Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…
Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Alistair Reid^1,2,3, Michael D Wiese⁴, Robert Metcalf⁵, Mihir D Wechalekar^6,7, Anita Lee^8,9, Catherine Hill^2,10,11, Cindy Hall⁸, Leah McWilliams⁵, Les Cleland⁸ and Susanna Proudman¹², ¹Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, ²Medicine, The University of Adelaide, Adelaide, Australia, ³Medicine, University of Wollongong, Wollongong, Australia, ⁴School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Rheumatology, Flinders University, Adelaide, Australia, ⁸Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁹Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁰The Queen Elizabeth Hospital, Adelaide, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].